Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?

Ilse Van Brussel, Amaryllis H. Van Craenenbroeck, Dorien M. Schrijvers, Nathalie Cools


Renal cell carcinoma (RCC) constitutes 80 to 85 percent of primary renal neoplasms in adults (1). Although surgical resection can be curative in localized disease, many patients eventually recur. Patients with locally advanced or metastatic disease have a poor prognosis, with a 5-year survival rate of less than 15%.